J.P. Morgan Sticks to Their Hold Rating for Acorda Therapeutics (ACOR)

By Austin Angelo

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Acorda Therapeutics (ACORResearch Report) on May 2 and set a price target of $18. The company’s shares closed yesterday at $12.10, close to its 52-week low of $9.58.

According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 0.6% and a 41.8% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., BioMarin Pharmaceutical Inc., and ACADIA Pharmaceuticals Inc.

Currently, the analyst consensus on Acorda Therapeutics is a Moderate Buy with an average price target of $21.60, a 78.5% upside from current levels. In a report issued on May 2, Stifel Nicolaus also maintained a Hold rating on the stock with a $12 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $36.35 and a one-year low of $9.58. Currently, Acorda Therapeutics has an average volume of 869.7K.

Based on the recent corporate insider activity of 80 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules.